INBX (Inhibrx Biosciences) Total Debt per Share: $12.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INBX Inhibrx Biosciences Inc INBX
10 GF Score
Price $120.18
! 2 Warning Signs
View Full Analysis

What is Inhibrx Biosciences Total Debt per Share?

Inhibrx Biosciences INBX +4.81% 10 Total Debt per Share is $12.35 as of Jun. 2026. GuruFocus rates INBX with a GF Score™ of 10/100. The stock has 2 warning signs investors should review.

$12.35 (As of Jun. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Inhibrx Biosciences's Total Debt Per Share for the quarter that ended in Jun. 2026 was $12.35.

Inhibrx Biosciences Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Inhibrx Biosciences's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Inhibrx Biosciences Total Debt per Share Chart

Inhibrx Biosciences Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Debt per Share
0.35 14.76 0.56 7.34

Inhibrx Biosciences Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.38 7.37 7.34 12.38 12.35
INBX
10GF Score
Inhibrx Biosciences Inc INBX
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Inhibrx Biosciences Total Debt per Share Calculation

Inhibrx Biosciences's Total Debt Per Share for the fiscal year that ended in Dec. 2025 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(104.69+2.33)/14.58
=7.34

Inhibrx Biosciences's Total Debt Per Share for the quarter that ended in Jun. 2026 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(179.14+2.49)/14.71
=12.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $12.35 mean?
Inhibrx Biosciences (INBX) has a Total Debt per Share of $12.35 as of Jun. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Inhibrx Biosciences and its competitors.
Is Inhibrx Biosciences' Total Debt per Share too high?
Inhibrx Biosciences' current Total Debt per Share is $12.35. Overall, Inhibrx Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Inhibrx Biosciences' Total Debt per Share compare to SEPN and NTLA?
Inhibrx Biosciences' Total Debt per Share of $12.35 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Biotechnology company?
A good Total Debt per Share depends on the Biotechnology industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Inhibrx Biosciences and its competitors. Inhibrx Biosciences's current Total Debt per Share is $12.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Inhibrx Biosciences stock overvalued right now?
Inhibrx Biosciences (INBX) has a current Total Debt per Share of $12.35. The current Total Debt per Share is $12.35. Inhibrx Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Inhibrx Biosciences (INBX), the current Total Debt per Share is $12.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Inhibrx Biosciences Business Description

Address 11025 N. Torrey Pines Road, Suite 140, La Jolla, CA, USA, 92037
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
10GF Score

Get the complete analysis for INBX

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$120.18
Price